Evaluation of lipoprotein (a) [Lp(a)] and lipid abnormalities in patients with newly detected hypertension and its association with severity of hypertension

Subodh Kumar Mahto¹, Ankita Sheoran¹, Adesh kisanji Gadpayle¹, Kritika Gupta¹, Pulin Kumar Gupta¹, Anubhuti Chitkara², Nagina Agarwal¹

Departments of ¹Medicine and ²Biochemistry, PGIMER, Dr. RML Hospital, New Delhi, India

Abstract

Introduction: Hypertension remains the major preventable cause of cardiovascular disease (CVD). Lipoprotein (a) is seen to be associated with established essential hypertension and contributes to atherogenesis or to thrombogenesis or both. aim: Correlation between lipoprotein (a) [Lp(a)] and lipid abnormalities in patients with newly detected hypertension and its association with severity of hypertension. Methods: It was a cross-sectional observational study carried out at PGIMER, DR. RML Hospital, New Delhi, India. Estimation of serum Lp (a) and lipid parameters along with routine laboratory investigations were carried out in 100 newly diagnosed cases with hypertension and compared with age and sex matched 50 healthy normotensive controls. Result: Amongst 100 cases the mean systolic and diastolic blood pressure was 160.68 ± 19.75 mmHg and 84.44 ± 4.32 mmHg respectively. The mean serum Lp (a) in cases was 34.03 ± 7.55 mg/dl as compared to 24.13 ± 4.41 mg/dl in controls (p < 0.0001). 62% of cases as compared to 12% of controls had elevated serum Lp (a) levels. Apart from that, the levels of Lp (a) and lipid parameters increased significantly with higher stage of disease (p < 0.0001). Approximately 8% of cases had left ventricular hypertrophy as compared to 1% of control. Similarly, 18% of cases had Non-alcoholic fatty liver disease as compared to 4% of controls. 5% of cases had retinopathy as compared to nil in controls. 4% of cases had microalbuminuria as compared to nil in controls. Conclusion: It was observed that newly detected hypertension is associated with major derangements of Lp (a) and lipid parameters. We also concluded that end organ involvement is significantly higher in newly detected hypertensives as compared to normotensive subjects and it was attributed to be due to lipid abnormalities observed in the group.

Keywords: Grading of hypertension, lipid profile, lipoprotein (a), newly detected hypertension

Introduction

The total number of people estimated to be suffering with hypertension is estimated to be 1.13 billion in 2015.[1] The prevalence of hypertension is 11.3% in India.[2] The overall prevalence of hypertension in adults is around 30-45%[3] with a global age standardized prevalence of 24% and 20% in men and women respectively.[3] Elevated blood pressure (BP) was the leading global contributor to premature deaths in 2015, accounting for almost 10 million deaths and over 200 million disability-adjusted life years. Systolic blood pressure (SBP) >140 mmHg accounts for most of the mortality and disability burden (70%) and the largest number of SBP-related deaths per
Dyslipidaemia is more common in hypertensives than normotensives and lipid levels increase as BP increases.[11] In hypertensive patients, a changes in the lipid profile has been observed, with increased levels of total cholesterol (TC), triglycerides (TG) and low density lipoprotein cholesterol (LDL-C) and low blood concentrations of high-density lipoproteins cholesterol (HDL-C) as compared to non-hypertensive.[12] Apart from that high plasma concentration of lipoprotein (a) [Lp(a)] has been found to be higher in these individuals as compared to healthy population and is found to be an independent risk factor for cardiovascular diseases in these patients.[13] The role of Lp(a) as an independent risk factor of vascular disease has been investigated for more than 20 years, but recently the European Atherosclerosis Society (EAS) has issued a new consensus statement endorsing routine measurement of Lp(a) among patients with moderate to high risk of cardiovascular disease.[14] With the results of HOPE-3[15] trial it is now proven beyond doubt that mortality reduction in hypertensive individuals after BP control is achieved maximally after suppression of lipid parameters even when they are minimally raised or within normal limits. It was seen that rosuvastatin to these hypertensive subjects with normal lipid parameters reduced subsequent CVD substantially. However the same is not well studied in treatment naïve newly detected hypertensive.

Specially studies on evaluation of Lp(a) and lipid abnormalities in newly detected hypertension are very scarce in India hence the present study was planned. The objectives of this research was to detect the prevalence of Lp(a) and lipid abnormalities in subjects with newly detected hypertension and their association with grades of hypertension.

Materials and Methods

It was a cross sectional observational study conducted at the department of Medicine, PGIMER, Dr RML Hospital, New Delhi, India over a span of two years.

100 consecutively newly diagnosed treatment naïve patients with hypertension as per European Society of Hypertension (ESH) and the European Society of Cardiology (ESC-2018)[16] [Table 1] were recruited as cases.

All hypertensive patients were graded according to the severity[17] thus:

Grade 1 = 140–159/90–99 mmHg,
Grade 2 = 160–179/100–109 mmHg, and
Grade 3 = >180/>110 mmHg.

50 non-hypertensive, age and sex matched, healthy volunteers were recruited as controls. The ethical clearance was taken from the institutional ethical review board committee (Number: 01-40/18/2013/IEC/Thesis/PGIMER-RMLH/10234). The cases and controls were recruited from the general outpatient clinics of the hospital. All cases with history of chronic alcoholism or smoking, renal disease (serum creatinine >1.5 mg/L), liver related disorder, diabetes mellitus, pregnancy, hypothyroidism/hyperthyroidism, history of CAD in the past, hypertriglyceridemia (>400 mg/dL) and hereditary familial hypercholesterolemia/dyslipoproteinemia were excluded. Patients taking phenytoin, carbamazepine, metformin, pentoxifylline, methotrexate, vitamin D supplements, and lipid lowering agents were also excluded. A detailed history was taken including past or current co-morbidities. Height was measured by a stadiometer, weight was recorded using a spring based weighing scale. BMI was calculated using the formula of BMI = Weight (in Kg)/Height² (in m).

Blood pressure was measured by using standard BP measurement protocol after the patient had rested for 10 minutes. Two measurements were taken by aneroid sphygmomanometer, with at least a 5-minute interval between successive measurements. The reading at the first appearance of the Korotkoff sound (phase I) was taken as the systolic blood pressure and that at its disappearance (phase V) was taken as the diastolic blood pressure.[18] Hypertension was defined as values >140 mmHg SBP and/or >90 mmHg DBP on two or more different occasions.[19]

After overnight fasting, 10 ml of venous sample was drawn for haematological and laboratory investigation including kidney function test (KFT), liver function test (LFT), complete lipid profile, Lp(a), and thyroid function test. Biochemical tests were performed by standard operating protocols (SOP) in the laboratories of department of Biochemistry and Pathology.

Table 1: Classification of blood pressure as per ESH/ESC-2018

| Category              | Systolic (mmHg) | Diastolic (mmHg) |
|-----------------------|-----------------|------------------|
| Optimal               | <120            | and              |
| Normal                | 120-129         | 80-84            |
| High-normal           | 130-139         | 85-89            |
| Grade 1 hypertension  | 140-159         | 90-99            |
| Grade 2 hypertension  | 160-179         | 100-109          |
| Grade 3 hypertension  | >180            | and/or >110      |
cholesterol, HDL-cholesterol, and triglycerides were measured by enzymatic method. Friedewald formula was used in the calculation of LDL Cholesterol as shown in the following:

\[
\text{LDL Cholesterol} = \text{total serum cholesterol} - (\text{HDL} + \text{total TG/5}) \text{mg/dL and VLDL} = 1/5 \text{triglyceride.}
\]

Lp(a) was measured by Immunoturbidimetry method (Normal serum level: <30 mg/dL).[14] Serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels were classified on the basis of the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III).[17]

**Statistical analysis**

Categorical variables were presented in number and percentage (%) and continuous variables were presented as mean ± SD and median. Normality of data was tested by Kolmogorov-Smirnov test. If the normality was rejected then non-parametric test was used. Quantitative variables were compared using Independent t test (as the data sets were normally distributed) between the two groups and ANOVA for more than two groups. A P value of <0.05 was considered statistically significant. The data was entered in MS EXCEL spreadsheet and analysis was done using Statistical Package for Social Sciences (SPSS) version 21.0.

**Results**

A total of 100 cases and 50 controls were recruited in this study. Out of 100 cases, 60 (60%) were males and 40 (40%) were females while Out of 50 controls, 30 (60%) were males and 20 (40%) were females. The mean age amongst cases was 43.06 ± 10.68 years and was 45.24 ± 11.31 years in controls. Majority (85%) of the cases and controls were less than 50 years of age. The mean body mass index (BMI) was 26.58 ± 9.5 kg/m² in cases and 24.13 ± 4.41 kg/m² in cases and controls respectively (p = 0.072). The mean serum Lp(a) was 34.03 ± 7.55 mg/dl and 24.13 ± 4.41 mg/dl in cases and controls respectively (p < 0.001). Out of 100 cases, 62% had raised Lp(a) whereas only 12% controls had raised Lp(a) (p < 0.0001). Even amongst controls, high Lp(a) levels were observed in those with blood pressure 130-139 mmHg systolic and 80-89 mmHg diastolic (i.e. pre hypertension/high normal). The mean value of total cholesterol (TC), and low density lipoprotein and (LDL-C) were significantly higher and mean value of HDL, was significantly lower in cases than in the controls (p < 0.001). There was no significant difference in levels of TG (p = 0.0747) amongst cases and controls. [Table 2]. 8% of cases had left ventricular hypertrophy (LVH) as compared to 1% of control (p < 0.497). Similarly, 18% of cases had Non-alcoholic fatty liver disease (NAFLD) as compared to 4% of controls (p < 0.939). 5% of cases had retinopathy as compared to nil in controls (p < 0.170). 4% of cases had microalbuminuria (MAU) as compared to nil in controls (p < 0.302). No case and control were found to have abnormal nerve conduction velocity (NCV). [Table 3].

**Discussion**

In our study, 62% of cases with newly detected hypertension had higher lipoprotein (a) as compared to 12% in controls. This is in accordance with the findings of Lima et al.[18] who stated that higher levels Lp(a) abnormality (62.5%) were seen irrespective of the size and degree of stenosis (mild/moderate and severe atheromatosis) in known hypertensives. Bhavani et al.[19] also found that in Indians, 40.5% of hypertensive patients had Lp(a) >30 mg/dl when compared to 10% in controls. Cataloni et al.[20] reported significantly elevated levels of plasma Lp(a) in 123 Caucasian essential arterial hypertensive patients (47 men and 76 women) and stated that 13% of hypertensive patients had Lp(a) >30 mg/dl when compared to 8% in controls. The prevalence of high had Lp(a) observed in our study was quite high (62% in patients and 12% in controls) when compared to the Caucasian population. This can be explained by the fact that Indian population by their genetic structure are prone to dyslipidaemia, especially hypertriglyceridemia. The prevalence of metabolic syndrome in Indians is higher and manifests earlier as compared to Caucasians. This unique genetic tendency superimposed with a high fat, high carbohydrate and low protein diet, may be the causative factor behind the dyslipidaemia and high Lp(a) which is seen in even 12% of our controls (almost equal to the prevalence of high Lp(a) seen in Caucasian hypertensives).

Our study did not find any correlation of lipoprotein and lipid levels to the age or sex of the patients. This is in accordance with other studies including by Osuji et al.[21] where no statistically significant relationship of sex with lipoprotein (a) and lipid levels...
Mahto, et al.: Evaluation of lipoprotein (a) [Lp(a)] and lipid in patients with newly detected hypertension and with severity of hypertension

### Table 2: Levels of Lipoprotein (a) and lipid parameters and percentage of participants with abnormal value in cases and controls

| Lipoprotein(a) and lipid parameters (in mg/dl) | Case (n=100) | Control (n=50) | P* | (%) of cases with abnormal value | (%) of controls with abnormal value |
|----------------------------------------------|--------------|---------------|----|---------------------------------|-----------------------------------|
| Lp (a)                                       | 34.03±7.55   | 24.13±4.41    | <0.001 | 62%                             | 12%                              |
| TC                                           | 213.72±43.32 | 168.1±32.11   | <0.001 | 60%                             | 12%                              |
| HDL-C                                        | 34.38±5.98   | 40.3±6.89     | <0.001 | 66%                             | 26%                              |
| LDL-C                                        | 138.08±40.64 | 99.8±67.07    | <0.001 | 30%                             | 4%                               |
| VLDL-C                                       | 36.48±10.99  | 27.88±8.27    | 0.08685 | 32%                             | 3%                               |
| TG                                           | 183.26±55.59 | 136.06±34.81  | 0.0747 | 62%                             | 30%                              |
| LDL/HDL                                      | 4.21±1.65    | 2.5±0.59      | <0.001 | 62%                             | 4%                               |
| TC/HDL                                       | 6.39±2.07    | 4.21±0.68     | <0.001 | 74%                             | 43%                              |

*Independent t-test. | Lipoprotein(a): [Lp (a)], Total cholesterol (TC), High density lipoprotein cholesterol (HDL-C), Low density lipoprotein cholesterol (LDL-C), Very low density lipoprotein cholesterol (VLDL-C), triglyceride (TG), Low density lipoprotein cholesterol (LDL)/ High density lipoprotein (HDL), Total cholesterol (TC)/ High density lipoprotein (HDL)*

### Table 3: Frequency of end organ damage in cases and controls

| End organ damage                  | Frequency of end organ damage in cases (n=100) | Frequency of end organ damage in controls (n=50) | P* |
|-----------------------------------|-----------------------------------------------|-----------------------------------------------|----|
| Left ventricular hypertrophy (LVH)| 8%                                           | 1%                                           | 0.497 |
| Non-alcoholic fatty liver disease (NAFLD) | 18%                                       | 4%                                           | 0.939 |
| Retinopathy                       | 5%                                           | 0%                                           | 0.170 |
| Micro albuminuria (MAU)           | 4%                                           | 0%                                           | 0.302 |
| Nerve conduction velocity (NCV)   | 0%                                           | 0%                                           | 0    |

*Independent t-test

### Table 4: Frequency of Lipoprotein (a) and lipid parameters abnormalities in cases with between different grades of hypertension and their comparison with controls

| Lipoprotein(a) and lipid parameters (in mg/dl) | Grade 1 hypertension n=58 | Grade 2 hypertension n=18 | Grade 3 hypertension n=24 | Control n=50 | P* |
|-----------------------------------------------|----------------------------|---------------------------|---------------------------|---------------|----|
| Lp (a)                                        | 31.11±4.5                  | 33.22±7.22                | 41.69±8.82                | 24.13±4.41    | <0.001 | 12.243 |
| (% of cases with abnormal value)              | 51%                        | 55%                       | 91.67%                    | 12%           |      |     |
| LDL-C                                         | 121.9±29.69                | 134.2±27.48               | 180.25±43.82              | 99.86±27.07   | <0.001 | 13.183 |
| (% of cases with abnormal value)              | 10.34%                     | 44.44%                    | 66.67%                    | 4%            |      |     |
| LDL/HDL                                       | 3.52±1.11                  | 4.15±0.99                 | 5.96±1.89                 | 2.5±0.59      | <0.001 | 14.813 |
| (% of cases with abnormal value)              | 41.38%                     | 100%                      | 100%                      | 4%            |      |     |
| HDL-C                                         | 362.6±84                   | 326.7±4.06                | 317.5±3.36                | 40.3±6.89     | 0.072  | 2.784 |
| (% of cases with abnormal value)              | 48.28%                     | 88.89%                    | 91.67%                    | 26%           |      |     |
| TC/HDL                                        | 5.49±1.75                  | 6.61±1.11                 | 8.39±1.97                 | 4.21±0.68     | <0.001 | 12.277 |
| (% of cases with abnormal value)              | 51.78%                     | 100%                      | 100%                      | 43%           |      |     |
| TC                                            | 192.72±29.98               | 213.33±23.53              | 264.75±40.82              | 168.1±32.11   | <0.001 | 21.594 |
| (% of cases with abnormal value)              | 41.38%                     | 66.66%                    | 60%                       | 12%           |      |     |
| TG                                            | 163.1±35.36                | 210.56±74.33              | 211.5±63.38               | 136.06±34.81  | 0.008  | 5.344 |
| (% of cases with abnormal value)              | 51.72%                     | 77.78%                    | 75%                       | 30%           |      |     |
| (VLDL-C)                                      | 32.93±7.26                 | 42±14.69                  | 40.92±12.92               | 27.88±8.27    | 0.023  | 4.084 |
| (% of cases with abnormal value)              | 14.24%                     | 55.56%                    | 50%                       | 3%            |      |     |

*ANOVA. F value is the value of ANOVA test. | Lipoprotein(a): [Lp (a)], Low density lipoprotein cholesterol (LDL-C), Low density lipoprotein cholesterol (LDL), Very low density lipoprotein cholesterol (VLDL-C), triglyceride (TG), Low density lipoprotein cholesterol (LDL)/ High density lipoprotein (HDL), Total cholesterol (TC)/ High density lipoprotein (HDL)*

could be proved. The mean value of lipoprotein (a) in our study was 34.03 mg/dl in hypertensive patients which was significantly high than that in controls and is almost the same as that found by Tewari et al.[21] Elevated serum Lp(a) could play an important role in essential hypertension pathogenesis and can be considered as an individual risk factor in hypertensive patients.[13] That may explain the high CVD prevalence as well as mortality in Indians as compared to others. High Lp(a) creates a proinflammatory and prooxidative condition in blood vessels which may result into more endothelial injury and more seepage of LDL and Lp(a) into arterial wall and further plaque formation.[22] Eventually, less of elasticity as well dispensability may happen leading to hypertension. A significantly higher level of total cholesterol, triglycerides and LDL were found in cases as compared to controls. Similarly, HDL-C was significantly lesser in cases than in controls. Results of our study are supported by those done by Lima M. et al.[18] where significantly higher levels of lipoprotein (a) and others lipid parameters were documented in hypertensive individuals on treatment as compared to normotensive people. Which can happen since many antihypertensive drugs specially
Hypertension and dyslipidaemia are two of the main risk factors for vascular diseases and are often associated with each other. The co-existence of these two risk factors has more than an additive adverse impact on the vascular endothelium, which results in enhanced atherosclerosis, leading to CVD. The exact mechanism by which a low HDL-C increases CVD risk has however not been fully elucidated although experimental studies suggest a direct role for HDL-C in promoting reverse cholesterol transport from foam cells in the atherosclerotic plaque depots in blood vessels to the liver for excretion. HDL-C also exhibits potent anti-inflammatory and antioxidant effects that inhibit the atherogenic process.[23, 24] It has additionally been shown that a low HDL-C level correlates with the presence of other atherogenic risk factor. Diastolic dysfunction was associated with severity of HTN which was significantly raised in stage II HTN patients. In early stages of HTN, diastolic filling disorder can arise in view of delayed relaxation of left ventricle and subsequently diastolic failure occurs as a consequence of poor left ventricle compliance.[25] In our study, statistical significant correlation of lipoprotein (a) and lipid parameters with the grade of hypertension was elucidated. This is in well accordance with other studies by in Dahlen et al.[26] who evaluated the relationship of level of plasma Lp(a) and the severity of CHD, as assessed by coronary angiography and found that not only are high plasma concentrations of Lp(a) associated with the presence of CHD, but they are also directly related to its severity.

Limitations of the study

It was a hospital based study, so it may not truly represent the population. Our study did not collect data from all parts of the country and at best it could only be speculated whether observed relationship is similar all over the country. Secondly being a cross-sectional study by design it cannot associate causal relationships between the factors under study. India is a diverse country with different religious and dietary practices which was not taken into account.

Conclusion

This study has shown that lipoprotein (a) and lipid abnormalities are highly prevalent among newly diagnosed hypertensive and the severity increases with increasing grades of hypertension. Approximately 10%–15% of our newly detected hypertension had end organ damage. So efforts should be intensified to diagnose hypertension as early as possible in general population and if present then complete evaluation and management including lipid and Lp(a) should be the utmost task. Any abnormalities detected are to be taken into the therapeutic considerations in these high-risk individuals. Early diagnosis and treatment of the disease can decrease the morbidity and mortality, and can prevent further complications. However, long term randomized prospective trials are required to elicit the effect of reduction of Lp(a) and lipid levels on the reduction of these complications.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017;389:37–55.
2. Gupta R, Gaur K, Venkata S, Ram C. Emerging trends in hypertension epidemiology in India. J Hum Hypertens 2019;33:575–87.
3. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. PURE Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959–68.
4. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015. JAMA 2017;317:165–82.
5. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet 2016;387:957–67.
6. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. I. Overview, meta-analyses, and metaregression analyses of randomized trials. J Hypertens 2014;32:2285–95.
7. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180–9.
8. Mancia G, Facchetti R, Bombelli M, Polo Friz H, Grassi G, Giannattasio C, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005;45:1072–7.
9. King P, Peacock I, Donnelly R. The UK prospective diabetics study (UKPDS): Clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999;48:643–5.
10. Lonn EM, Bosch J, Lopez-Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2009–20.
11. Borghi C. Interactions between hypercholesterolemia and hypertension: Implications for therapy. Curr Opin Nephrol Hypertens 2002;5:489-96.
12. Gebrie A, Gnanasekaran N, Menon M, Sisay M, Zegeye A. Evaluation of lipid profiles and hematological parameters in hypertensive patients: Laboratory-based cross-sectional study. SAGE Open Med. 2018;6:2050312118756663. doi: 10.1177/2050312118756663.
13. Cataloni M, Perilli E, Carzaniga G, Colomobo F, Catrola M,
Andreoni S. Lp(a) in Hypertensive patients. J Hum Hypertens 1998;12:83-9.

14. European Atherosclerosis Society (EAS). New recommendations from the European Atherosclerosis Society consensus panel resolve controversy about lipoprotein (a) and cardiovascular risk. 2010. Available from: http://www.diabetesincontrol.com/european-atherosclerosis-society-recommends-screening-for-lpa/.

15. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021-104.

16. Manocha A, Srivastava LM. Lipoprotein (a): A unique independent risk factor for coronary artery disease. Indian J Clin Biochem 2016;31:13–20.

17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421.

18. Lima LM, Carvalho Md, Loures-Vale AA, Fernandes AP, Mota AP, Neto CP, et al. Increased serum levels of lipoprotein (a) correlated with the severity of coronary artery disease in patients submitted to angiography. Arq Bras Cardiol 2006;86:506-11.

19. Bhavani BA, Padma T, Sastry B, Reddy NK. Plasma Lipoprotein (a) levels in patients with untreated essential hypertension. Indian J Hum Genet 2003;9:65-8.

20. Osuji CU, Omejua EG, Onwubuya EI, Ahaneku GI. Serum lipid profile of newly diagnosed hypertensive patients in new, South-East Negeria. Int J Hypertens 2012;2012:710486. doi:10.1155/2012/710486

21. Tewari S, Gupta D, Kumar S, Garg N, Godbole MM, Sinha N. Plasma Lipoprotein (a) levels in patients with pulmonary arterial hypertension. Indian Heart J 2001;53:56-60.

22. Kropiewnicka EH, Paczek L. The importance of advanced glycosylation end products in the creation and progression of atherosclerosis in non-insulin-dependent diabetes mellitus. Przegl Lek 2000;57:283–7.

23. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circulation Res 2004;95:764-72.

24. Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 2000;11:383-8.

25. Prakash D. Target organ damage in newly detected hypertensive patients. J Family Med Prim Care 2019;8:2042-6.

26. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kaatz JA, Gotto AM Jr. Association of levels of lipoprotein Lp (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:738-65.